Jim Simons Kinnate Biopharma Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Kinnate Biopharma Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 887,740 shares of KNTE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

887,740

Previous 574,979 54.4%

Holding current value

Previous $1.36 Million 73.22%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$2.24 - $2.66 $700,584 - $831,944	312,761 Added 54.4%	887,740 $2.36 Million
Q4 2023 Feb 13, 2024	BUY	$1.07 - $2.5 $73,854 - $172,557	69,023 Added 13.64%	574,979 $1.36 Million
Q3 2023 Nov 14, 2023	BUY	$1.38 - $3.31 $232,055 - $556,596	168,156 Added 49.78%	505,956 $708,000
Q2 2023 Aug 11, 2023	BUY	$2.33 - $6.84 $529,609 - $1.55 Million	227,300 Added 205.7%	337,800 $1.02 Million
Q1 2023 May 12, 2023	BUY	$3.46 - $7.98 $24,566 - $56,658	7,100 Added 6.87%	110,500 $691,000

Q4 2022 Feb 13, 2023	BUY	$5.26 - $12.19 $15,254 - $35,351	2,900 Added 2.89%	103,400 $631,000
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $48,314 - $77,224	4,900 Added 5.13%	100,500 $1.2 Million
Q2 2022 Aug 12, 2022	BUY	$7.43 - $13.0 $532,731 - $932,100	71,700 Added 300.0%	95,600 $1.21 Million
Q1 2022 May 13, 2022	BUY	$7.73 - $17.99 $184,747 - $429,960	23,900 New	23,900 $269,000
Q4 2021 Feb 11, 2022	SELL	$16.5 - $25.48 $385,407 - $595,161	-23,358 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$17.81 - $24.87 $223,373 - $311,919	-12,542 Reduced 34.94%	23,358 $538,000
Q2 2021 Aug 13, 2021	BUY	$22.19 - $31.55 $796,621 - $1.13 Million	35,900 New	35,900 $836,000

Others Institutions Holding KNTE

# of Institutions

Shares Held

32.9M

Call Options Held

94.7K

Put Options Held

802K

View Full List

About Kinnate Biopharma Inc.

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

More about KNTE

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account